Do Today’s Updates Make DX (Group) PLC, British Polythene Industries plc And Proteome Sciences plc 3 ‘Must-Have’ Stocks?

Should you buy these 3 stocks right now? DX (Group) PLC (LON: DX), British Polythene Industries plc (LON: BPI) and Proteome Sciences plc (LON: PRM).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in mail, parcels and logistics network operator DX (LSE: DX) have fallen by as much as 20% today after it released a rather disappointing set of half-year results.

Despite being in line with revised management expectations, DX posted a fall in revenue and pre-tax profit, with the former falling by 3.9% and the latter by 86.9% versus the same period of the previous year. The key reason for this is a challenging trading environment, with DX implementing measures to try and overcome such difficulties.

For example, it has completed the managed exit of a number of unattractive contracts and has enjoyed some success in securing new contracts on more favourable terms. Furthermore, DX believes that it will meet current guidance for the full-year and is focused on positioning itself for long-term growth, with its strategic OneDX programme set to improve financial performance in the coming years. However, it may be a stock to watch rather than buy at the present time given the scope for further short-term disappointment.

Value for money

Also reporting today was British Polythene (LSE: BPI), with its shares rising by 7% after it delivered an increase in pre-tax profit. It rose by over 4% despite revenue coming under pressure after total volumes declined due to lower demand from multiple UK sectors. Sales were also hurt somewhat by reduced polymer prices and the impact of currency headwinds.

But with its North American division moving back into the black, British Polythene’s overall profit improved and this has enabled it to increase dividends for the full-year by 12.5%. This puts it on a yield of 2.8% which, while low, is covered 3.9 times by profit. This indicates that rapid dividend growth is on the cards and with British Polythene trading on a price-to-earnings (P/E) ratio of just 9.4, it offers huge upward rerating potential, too.

Despite the challenges that British Polythene faces, it seems to offer excellent value for money. That’s especially the case since earnings are due to rise by 5% in each of the next two years, thereby showing that it’s set to perform relatively well even during a rather difficult period.

Take a risk?

Meanwhile, shares in biotech company Proteome Sciences (LSE: PRM) have risen by over 8% today following the release of an upbeat trading update. The company has reported a positive start to the 2016 financial year, with a strong order book and a growing pipeline in biomarker services.

Notably, following the addition of a further Fusion mass spectrometer in the latter part of 2015, the increased capacity that it brought (through doubling the levels of SysQuant/TMTcalibrator production) is being fully utilised this year. In fact, it has resulted in four customer projects already being completed and an increase in customer enquiries. In addition, partnering has also started well in 2016 and Proteome Sciences is optimistic regarding its long-term prospects.

Clearly, Proteome Sciences may be of interest to less risk-averse investors, although it remains a lossmaking smaller company and therefore, most investors may find more appealing risk/reward ratios elsewhere.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »